Skip to content

Development and Application of a New Balloon Catheter for Intraairway Hemostasis

Development and Application of a New Balloon Catheter for Intraairway Hemostasis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05554731
Enrollment
200
Registered
2022-09-26
Start date
2022-10-01
Completion date
2023-10-30
Last updated
2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemoptysis

Brief summary

Massive hemoptysis is a serious disease of respiratory system, which seriously endangers the life of patients. There are obvious difficulties in the treatment of hemoptysis. In the traditional treatment, patients still have the risk of massive hemoptysis and suffocation, and the risk control in the treatment process cannot be ensured. Intra - airway interventional therapy, especially the hemostatic technique of intra - airway balloon catheter, is an important means to control the risk of hemoptysis. However, the current intraairway balloon catheter therapy technology is immature, complicated and difficult to operate, and the cost is high. There is a lack of special balloon for hemostasis, and the balloon borrowed for other purposes cannot meet the needs of hemoptysis treatment. Therefore, it is urgent to develop a new balloon catheter for airway hemostasis, which has simple technical operation, easy to master and popularize, efficient and safe function and structure. According to this requirement, this project designed and developed hemostatic balloon catheter with multiple functions such as self-guiding, anti-displacement, anti-leakage and detachable rear end, so as to make the treatment of massive hemoptysis more safe and effective, simpler and faster, so as to be widely applied in clinical practice.

Detailed description

This study are aimed to investigate the safety and effectiveness of the new intraairway hemostatic balloon catheter in the treatment of massive hemoptysis, as well as the superior efficacy compared with the traditional treatment strategy of massive hemoptysis.

Interventions

DEVICEa New Balloon Catheter for Intraairway Hemostasis

In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.

DEVICETraditional Therapy

A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.

Sponsors

First Affiliated Hospital of Wenzhou Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* The patients were 18-75 years, male or non-pregnant female; * Meet the clinical definition of massive hemoptysis (blood loss ≥100ml each time or ≥500ml 24h); * The patient/legal authorized representative understood the purpose and procedure of the test and voluntarily signed the informed consent.

Exclusion criteria

* Patients and their family members have no subjective treatment intention;Patients fail to cooperate or sign preoperative informed consent; * The obvious effect of balloon catheter therapy is not ideal; * Severe arrhythmia, acute myocardial ischemia; * blood pressure is not effectively controlled (diastolic blood pressure ≥95mmHg or systolic blood pressure ≥150mmHg); * Severe coagulopathy; * Severe organ insufficiency (except respiratory insufficiency); * Allergic to narcotic drugs; * Pregnant women, those who are breast-feeding or trying to conceive; * Patients who do not wish to sign informed consent; * Patients who failed to follow up; * Other patients deemed unsuitable for the study by the investigator.

Design outcomes

Primary

MeasureTime frameDescription
Immediate intraoperative success rateImmediately after surgeryImmediate intraoperative success rate
Success rate of hemostasis 1 day after operation1 day after operationSuccess rate of hemostasis 1 day after operation
Intraoperative complicationDuring surgerySignificant increase in hemoptysis requiring other emergency management or suspension of operations, asphyxia, death, new arrhythmias, persistent worsening hypoxemia.

Secondary

MeasureTime frameDescription
Measurement indexes of follow-up treatment measuresFrom date of randomization until the date of second operation , assessed up to 13 monthsIncluding CTA and its preparation time, rate of arterial embolization surgery and proportion of emergency surgery.
Anesthesia complicationsDuring surgeryComplications after anesthesia including hypotension and shock, postoperative new tracheal intubation, coma and cerebrovascular accident.
hyoxemiaFrom date of randomization until the date of second operation , assessed up to 13 monthsFor more than 2 hours, oxygen saturation drops below 90%.
Other complicationsFrom date of randomization until the date of second operation , assessed up to 13 monthsvenous thrombosis of lower limbs
Balloon closure operation timeup to 13 monthsCompared with the traditional dilated balloon group, the operation time of balloon closure was calculated
success rate of placementFrom date of randomization until death , assessed up to 13 monthssuccess rate of placement
Success rate of hemostasis 3 days and 1 and 2 weeks after operation3 days and 1 and 2 weeks after operationSuccess rate of hemostasis 3 days and 1 and 2 weeks after operation
incidence of balloon displacementFrom date of randomization until the date of second operation , assessed up to 13 monthsincidence of balloon displacement (including the discount and distortion in the airway)
Nasal and bronchial mucosa injuryup to 13 monthsCompared with the traditional dilated balloon group, the damage of nasal and bronchial mucosa after balloon closure was observed
Rate of hemoptysis after balloon occlusionup to 13 monthscompared with traditional balloon dilation group
Rate of re-balloon closureup to 13 monthscompared with traditional balloon dilation group
Incomplete completion rate of balloon closure operationup to 13 monthscompared with traditional balloon dilation group
time and incidence of balloon leakageFrom date of randomization until the date of second operation , assessed up to 13 monthstime and incidence of balloon leakage (under the premise of two inflations per day)
The bleeding timeFrom date of randomization until the date of second operation , assessed up to 13 monthsThe bleeding time
The operation rate of balloon occlusion againFrom date of randomization until the date of second operation , assessed up to 13 monthsThe operation rate of balloon occlusion again

Countries

China

Contacts

Primary ContactChen ChengShui, doctor
wzchencs@163.com86-13806889081
Backup ContactLi Yuping, doctor
wzliyp@163.com86-13587600968

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026